ABBOTT PARK, Ill., March 6, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has cleared its FreeStyle Libre 2 and FreeStyle Libre 3 integrated ...

First and only continuous glucose monitoring system to be nationally reimbursed in France for people who use once-daily (basal) insulin 1 Expanded reimbursement facilitates wider access to continuous ...

Abbott has received CE Mark clearance for the second generation of its Freestyle Libre device, which will allow the company to make the device available to users in Europe. It will be rolled out ...

Abbott Laboratories ABT recently announced that the FreeStyle Libre 2 system's reimbursement coverage has been expanded by the French health authority to cover individuals using basal insulin as part ...

Please provide your email address to receive an email when new articles are posted on . A voluntary medical device correction warned users of three Abbott FreeStyle Libre readers about the risk of ...

Abbott’s continuous glucose monitoring system, the FreeStyle Libre 2, has been approved in Canada for adults and children four years and older with diabetes. The FreeStyle Libre 2 system continuously ...

Abbott’s latest innovation, the FreeStyle Libre® 2 Plus sensor, is available for the first time for t:slim X2™ insulin pump users in the U.S. Tandem’s Control-IQ™ hybrid closed-loop technology now ...

Abbott Laboratories received U.S. FDA clearance for the Freestyle Libre 2 and Freestyle Libre 3 continuous glucose monitoring (CGM) sensors for integration with automated insulin delivery (AID) ...

The medtech’s FreeStyle Libre 2 system also showed improvements in user-reported surveys that tracked the burdens associated with constantly being aware of changing glucose levels. The study’s results ...

Abbott Laboratories has initiated a voluntary medical device correction pertaining to its FreeStyle Libre, FreeStyle Libre 14 day, and FreeStyle Libre 2 Readers, stating that a limited number of ...